{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:19Z","timestamp":1777934539529,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Simplivia Healthcare Ltd, Kiryat Shmona, Israel"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Purpose<\/jats:title>\n The purpose of this study was to test the efficacy of ChemfortTM, an air filtration closed-system drug transfer device to prevent release of chemotherapy drug vapors and aerosols under extreme conditions. The air cleaning system is based on the adsorption of drug vapors by an activated carbon filter in the Vial Adaptor before the air is released out of the drug vial. The functionality of the carbon filter was also tested at the end of device\u2019s shelf life, and after a contact period with drug vapors for 7 days. Cyclophosphamide and 5-fluorouracil were the chemotherapy drugs tested.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The Vial Adaptor was attached to a drug vial and both were placed in a glass vessel. A needle was punctured through the vessel stopper and the Vial Adaptor septum to allow nitrogen gas to flow into the vial and to exit the vial via the air filter into the glass vessel which was connected to a cold trap. Potential contaminated surfaces in the trap system were wiped or rinsed to collect the escaped drug. Samples were analyzed using liquid chromatography tandem mass spectrometry.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Cyclophosphamide and 5-fluorouracil were detected on most surfaces inside the trap system for all Vial Adaptors without an activated carbon filter. Contamination did not differ between the Vial Adaptors with and without membrane filter indicating no effect of the membrane filter. The results show no release of either drug for the Vial Adaptors with an activated carbon filter even after 3 years of simulated aging and 7 days of exposure to drug vapors.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Validation of air cleaning CSTDs is important to secure vapor and aerosol containment of chemotherapy and other hazardous drugs. The presented test method has proven to be appropriate for the validation of ChemfortTM Vial Adaptors. No release of cyclophosphamide and 5- fluorouracil was found even for Vial Adaptors after 3 years of simulated aging and 7 days of exposure to drug vapors.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552211030682","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T02:35:17Z","timestamp":1625625317000},"page":"1508-1515","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Validation of chemotherapy drug vapor containment of an air cleaning closed-system drug transfer device"],"prefix":"10.1177","volume":"28","author":[{"given":"Galit","family":"Levin","sequence":"first","affiliation":[{"name":"Simplivia Healthcare Ltd, Kiryat Shmona, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-0044","authenticated-orcid":false,"given":"Paul JM","family":"Sessink","sequence":"additional","affiliation":[{"name":"Exposure Control Sweden AB, Bohus-Bj\u00f6rk\u00f6, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"bibr1-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93148-I"},{"key":"bibr2-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1136\/oem.49.12.855"},{"key":"bibr3-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1179\/oeh.1997.3.4.254"},{"key":"bibr4-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp155oa"},{"key":"bibr5-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000246827.44093.c1"},{"key":"bibr6-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6955-9-15"},{"key":"bibr7-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000249"},{"key":"bibr8-10781552211030682","first-page":"271","volume":"58","author":"Fransman W","year":"2014","journal-title":"An Occup Hyg"},{"key":"bibr9-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.22711"},{"key":"bibr10-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1080\/00039896.1994.9940377"},{"key":"bibr11-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4878(00)00050-8"},{"key":"bibr12-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5718(00)00105-4"},{"key":"bibr13-10781552211030682","first-page":"331","volume":"268","author":"Kiffmeyer TK","year":"2002","journal-title":"Pharm J"},{"key":"bibr14-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1093\/annweh\/wxz010"},{"key":"bibr15-10781552211030682","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1078155207082350","volume":"13","author":"International Society of Oncology Pharmacy Practitioners","year":"2007","journal-title":"J Oncol Pharm Practice"},{"key":"bibr16-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197172"},{"key":"bibr17-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217726160"},{"key":"bibr18-10781552211030682","volume-title":"NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings","author":"National Institute for Occupational Safety and Health"},{"key":"bibr19-10781552211030682","first-page":"95","volume":"52","author":"Nygren O","year":"2008","journal-title":"Ann Occup Hyg"},{"key":"bibr20-10781552211030682","first-page":"53803","volume":"80","author":"National Institute for Occupational Safety and Health","year":"2015","journal-title":"Fed Regist"},{"key":"bibr21-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218787256"},{"key":"bibr22-10781552211030682","volume":"81","author":"National Institute for Occupational Safety and Health","year":"2016","journal-title":"Fed Regist"},{"key":"bibr23-10781552211030682","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205263"},{"key":"bibr24-10781552211030682","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211030682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211030682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211030682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:12Z","timestamp":1777688712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211030682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211030682"],"URL":"https:\/\/doi.org\/10.1177\/10781552211030682","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}